Goldman Sachs Resumes Darden Restaurants (DRI) at Buy, A Bright Spot In Casual Dining
Tweet Send to a FriendGet Alerts DRI Hot Sheet
Price: $52.90 -0.43%
Rating Summary:
6 Buy, 16 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 21
Rating Summary:
6 Buy, 16 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 21
Trade DRI Now!
Goldman Sachs resumes coverage on Darden Restaurants (NYSE: DRI) with a Buy rating and $53 price target, suggesting 17% upside.
The firm notes DRI owns s three of the four highest scoring brands in their restaurant survey and has future growth potential from LongHorn. In addition, profitability is exceptionally strong, FCF is staple-like in its consistency and the company is shareholder friendly with respect to its cash deployment.
Goldman expects double-digit EPS growth for each of the next several years.
For more ratings news on Darden Restaurants click here and for the rating history of Darden Restaurants click here.
Shares of Darden Restaurants closed at $45.91 yesterday, with a 52 week range of $40.69-$53.74.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm notes DRI owns s three of the four highest scoring brands in their restaurant survey and has future growth potential from LongHorn. In addition, profitability is exceptionally strong, FCF is staple-like in its consistency and the company is shareholder friendly with respect to its cash deployment.
Goldman expects double-digit EPS growth for each of the next several years.
For more ratings news on Darden Restaurants click here and for the rating history of Darden Restaurants click here.
Shares of Darden Restaurants closed at $45.91 yesterday, with a 52 week range of $40.69-$53.74.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Keryx Biopharma (KERX) Patents Strong; JPMorgan Starts at Overweight
- Maxim Group Starts Agenus (AGEN) at Buy, PT $19
- Goldman Sachs Upgrades Enbridge (ENB) to Conviction Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Goldman SachsLogin with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

